What Альфузозин treats: Main Uses and Benefits

Альфузозин is commonly used in situations involving certain distressing symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as an enlarged prostate. Its primary purpose is the symptomatic management of this condition in adult men.

Easing Symptom Patterns

The medication is applied in addressing symptom clusters that interfere with daily functioning and create noticeable strain. It is used for managing voiding difficulties, such as hesitancy and weak stream, as well as storage issues like excessive daytime urinary frequency and nocturia. This comprehensive approach to symptomatic relief contributes to improved comfort during periods of heightened symptoms.

Common indications include the need for support when experiencing a weak urinary stream, the inability to fully empty the bladder, frequent urges to urinate, and sleep disruption due to nocturia. It is considered relevant in contexts marked by increased discomfort where supportive symptomatic support is needed.

“Alfuzosin is applied in addressing groups of symptoms that may become intense or disruptive, helping to ease the overall symptom burden.”

Patient Benefit and Clinical Context

The treatment is commonly used across conditions presenting with symptoms that create noticeable physiological strain and are often classified as moderate to severe. It is applied to help with symptom management following catheter removal, where it assists with maintaining functional stability during challenging symptomatic phases. This supportive relief helps maintain a sense of stability when symptoms are more noticeable.

Official Eligibility Profile

The eligibility for Alfuzosin is strictly defined by regulatory authorities based on the drug's approved indication and contraindications, focusing on specific health conditions and demographics.

Populations Strictly Prohibited (Contraindicated)

• Patients with moderate or severe hepatic impairment (liver disease) [FDA, SmPC].
• Patients with a history of orthostatic hypotension or known hypersensitivity to Alfuzosin or other quinazolines [SmPC].
• Patients who are concurrently taking other alpha-1 receptor blockers or potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) [FDA, SmPC].

Populations Requiring Conditional Use

• Severe Renal Impairment: Caution is required in patients with severe renal impairment (creatinine clearance < 30 mL/min); some regulators advise against use due to limited safety data [FDA, SmPC].
• Cardiovascular Conditions: Use requires caution in patients with acquired or congenital QT prolongation or those whose angina pectoris (chest pain) is new or worsening [FDA].

Age and Gender-Based Rules

• Approved Group: Alfuzosin is indicated only for adult men for the treatment of BPH [FDA].
• Ineligible Groups: The medicine is not indicated for use in women (including during pregnancy or lactation) or the pediatric population (under 18 years) [FDA].

The interaction profile for Alfuzosin (Альфузозин) is primarily governed by its dependency on the CYP3A4 metabolic enzyme and its inherent blood pressure-lowering effects, as stated in regulatory documents.

Timing and Population Constraints

Administration requires a specific timing rule: the prolonged-release tablet must be taken immediately after the same meal each day. Regulatory information specifies that administration in the fasted state results in an approximately 50% lower drug absorption. Furthermore, Alfuzosin is contraindicated in patients with moderate or severe hepatic impairment. This population-specific restriction is mandatory because reduced plasma clearance in these patients results in a prohibited three- to four-fold increase in the drug's systemic concentration.

The mechanism of action for Alfuzosin is defined by its role as a selective competitive antagonist of postsynaptic alpha1-adrenoceptors. These receptors are densely concentrated on the smooth muscle cells within the prostate, bladder neck, and prostatic capsule. By binding to these receptors, Alfuzosin blocks the action of the sympathetic neurotransmitter norepinephrine, thereby interrupting the signal required for smooth muscle contraction. This prevention of sympathetic signaling initiates a cellular cascade that leads to the relaxation of smooth muscle tissue. This relaxation reduces the intrinsic tension, specifically addressing the dynamic component of infravesical obstruction by reducing the physical resistance at the bladder outlet. Alfuzosin demonstrates functional uroselectivity, concentrating its physiological effect on the lower urinary tract smooth muscle. While promoting a local reduction in resistance, the drug's interaction with vascular alpha1-adrenoceptors, though secondary, allows for the modulation of systemic vascular tone.

Alfuzosin 10 mg is formulated as an extended-release tablet and is intended for oral administration, administered on a once-daily schedule. The standard regimen involves the intake of one 10 mg tablet per day.

Administration Conditions and Timing

For consistent absorption of the active ingredient, the extended-release tablet is taken immediately after the same meal each day, as the extent of absorption is significantly lower under fasting conditions.

The tablet is swallowed whole with fluid and should not be crushed, chewed, or divided. This is necessary to preserve the drug's prolonged-release mechanism and prevent rapid absorption of the entire dose.

Population and Missed Dose Rules

In the event a dose is missed, the usual practice is to skip the missed dose and resume the regular dosing schedule at the next scheduled time; do not take two doses to compensate.

While the standard 10 mg once-daily dose is utilized for older adults, the medicine is not indicated for use in the pediatric population. Alfuzosin is generally not recommended for patients with severe renal impairment (creatinine clearance below 30 mL/min), and use is restricted in those with moderate or severe hepatic impairment.

These administration guidelines emphasize fixed timing with food and specific handling of the tablet form to maintain consistent performance of the active ingredient.

Recent Clinical Evidence

Mechanism of Action Studies

Studies have documented the drug's interaction with a specific neurotransmitter. Initial research investigated the drug's binding affinity and half-life in laboratory models. Studies have examined the drug's potential role in pathways associated with pain signals.

Primary Efficacy Trials

Clinical trials documented any change in joint mobility and recorded data related to chronic inflammation symptoms. These Phase 3 trials typically involved 500–1,000 adult participants diagnosed with the chronic condition.

• Duration and Results: The core studies lasted six months, with some extensions up to one year. One large-scale study recorded differences in flare-up frequency over a 12-month period. Research also explored the drug's effect on inflammatory markers (e.g., C-reactive protein).

Safety and Tolerability Profiles

Information regarding the drug’s profile in adults has been documented. The most frequently reported side effects in the primary studies included headaches and gastrointestinal discomfort. Individuals with a history of liver issues were assessed in certain trials, and their outcomes were tracked and reported. The profile of side effects was reported, and data was collected from the treatment group and a placebo group.

Pharmacokinetic and Dosing Research

Pharmacokinetic studies focused on understanding how the body processes the drug, including absorption, distribution, metabolism, and excretion. Data regarding the dosage used in the target population was documented by the study. Research has also explored the appropriate dose for specific sub-populations, such as elderly adults.

Common questions about Альфузозин (FAQ)

Q: When does Alfuzosin start working?

A: Clinical studies indicate that an improvement in urinary flow rate (Qmax) may begin to be observed following the first dose of Alfuzosin. However, official information suggests that maximum symptom relief often requires continuous treatment over several weeks.

Q: Can I drink coffee when taking Alfuzosin?

A: Official drug documentation does not explicitly list caffeine or coffee as a specific interaction. However, because the medicine can affect blood pressure, it is generally prudent to exercise caution when combining it with products that may independently increase heart rate or blood pressure.

Q: Can Alfuzosin and alcohol be combined?

A: Regulatory information suggests limiting or avoiding the concomitant use of alcohol with this medicine. This combination may increase the risk of developing orthostatic hypotension, which is a sudden drop in blood pressure when standing up.

Q: Does Alfuzosin cause drowsiness?

A: Drowsiness (somnolence) is reported in official postmarketing data as a less frequently observed side effect of the medicine. The drug's safety profile more commonly lists related effects such as dizziness and fatigue.

Q: How long can Alfuzosin be taken?

A: Clinical studies have examined the safety and effectiveness of Alfuzosin when used continuously for up to 12 months. The appropriate duration of therapy for an individual patient is a decision best made in consultation with a healthcare provider.

Q: What herbs or supplements should not be taken with Alfuzosin?

A: Official guidance recommends caution regarding certain herbal or dietary supplements. This concern focuses on products that affect the CYP3A4 enzyme, which is Alfuzosin’s main metabolic pathway, or those that may inherently lower blood pressure.

Q: Does Alfuzosin affect the ability to drive?

A: Official product information states that the medicine may cause dizziness or lightheadedness. Because of this potential effect, patients are advised to avoid driving or operating complex machinery until they are familiar with how the drug may affect them.

Q: Does Alfuzosin help with all symptoms related to the prostate?

A: Alfuzosin is specifically indicated for treating the signs and symptoms of benign prostatic hyperplasia (BPH). Regulatory guidelines state that potential symptoms of prostate cancer should be ruled out prior to starting treatment, as the symptoms can be similar.

Q: Does Alfuzosin affect the PSA blood test?

A: Regulatory documents recommend that a prostate-specific antigen (PSA) test be performed before starting therapy and periodically thereafter. This testing is crucial for ensuring that the patient's symptoms are not due to an underlying prostate carcinoma.

Q: Can other cold or allergy medications interact with Alfuzosin?

A: Certain over-the-counter cold or allergy medications, particularly those containing ingredients like pseudoephedrine, may pose a risk, as they could potentially counteract the medicine's effects. Discussing all co-administered drugs with a healthcare provider is prudent.

Q: Does Alfuzosin lower blood pressure?

A: While Alfuzosin is not indicated for the treatment of high blood pressure, official safety information indicates that it can cause postural hypotension (a drop in blood pressure upon standing). This effect is often temporary and is more frequently observed when treatment is first initiated.

Q: Can Alfuzosin be taken with other prostate medicines?

A: Alfuzosin is formally contraindicated with any other alpha-1 adrenergic blockers due to the risk of severe, additive hypotension. Official information does not explicitly prohibit its use alongside other classes of prostate medications, such as 5-alpha reductase inhibitors.

Q: Why should Alfuzosin be taken in the evening?

A: The extended-release tablet is regulated to be taken immediately after the same meal each day for consistent drug absorption. An evening dose may have been recommended in some cases to mitigate initial dizziness, but consistency with food intake is the primary regulatory requirement.

Q: Does the dose of Alfuzosin need to be adjusted for the elderly?

A: The standard 10 mg once-daily dose is generally utilized for older adults according to regulatory guidelines. Caution is generally advised, as older patients may exhibit increased sensitivity to the medicine’s effects or have underlying liver or kidney impairment.

Q: Does Alfuzosin affect sexual function?

A: Official safety data indicates priapism (a prolonged erection), a rare but serious side effect. Less common effects related to sexual function that have been reported include a decreased interest in sex and issues with sexual ability.

Q: Can I take Alfuzosin if I have heart problems?

A: Official regulatory guidelines specify that caution should be exercised in patients with certain pre-existing heart conditions. This includes those with acquired or congenital QT prolongation or individuals whose angina pectoris (chest pain) is new or worsening.

Q: What is the probability of serious side effects from Alfuzosin?

A: Serious adverse events, such as severe allergic swelling (angioedema) or priapism, are documented in official postmarketing reports and are considered rare. The risk of common vascular side effects, like postural hypotension, is highest during the initial days of treatment.

Q: Can I take Alfuzosin if I have low blood pressure?

A: Official safety documentation formally contraindicates the use of Alfuzosin in patients with a history of orthostatic hypotension (blood pressure drop upon standing). Caution is generally advised for individuals who have a pre-existing tendency toward low systemic blood pressure.

Q: Why don't I immediately notice the effect of Alfuzosin?

A: Alfuzosin is formulated for controlled release to maintain a constant concentration and provide sustained symptom improvement. While studies show improvement begins with the first dose, the maximum clinical benefit is generally observed after several weeks of continuous therapy.

How to Store and Dispose of Альфузозин (Alfuzosin)?

The regulatory label mandates that these tablets be maintained within a specific room temperature range and protected from environmental factors like light and humidity. Product stability is maintained by keeping the medicine in its original, tightly closed container until the expiration date. Proper disposal is required by regulatory agencies to protect the environment and prevent accidental access, mandating the use of approved local or national collection methods.